scholarly journals HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-γ/RANKL Cross-talk

2003 ◽  
Vol 278 (48) ◽  
pp. 48251-48258 ◽  
Author(s):  
J. Mohamad Fakruddin ◽  
Jeffrey Laurence
Keyword(s):  
Protease Inhibitors ◽  
Cross Talk ◽  
Nuclear Factor Κb ◽  
Interferon Γ ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors ◽  
Nuclear Factor ◽  
Receptor Activator ◽  
Hiv Envelope ◽  
Envelope Gp120

scholarly journals Cross-Talk of Receptor Activator of Nuclear Factor-κB Ligand Signaling With Renin–Angiotensin System in Vascular Calcification

2013 ◽  
Vol 33 (6) ◽  
pp. 1287-1296 ◽  
Author(s):  
Mariana Kiomy Osako ◽  
Hironori Nakagami ◽  
Munehisa Shimamura ◽  
Hiroshi Koriyama ◽  
Futoshi Nakagami ◽  
...  
Keyword(s):  
Vascular Calcification ◽  
Cross Talk ◽  
Renin Angiotensin System ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Receptor Activator

scholarly journals Cross-Talk between the Interleukin-6 and Prostaglandin E2 Signaling Systems Results in Enhancement of Osteoclastogenesis through Effects on the Osteoprotegerin/Receptor Activator of Nuclear Factor-κB (RANK) Ligand/RANK System

Endocrinology ◽  
2005 ◽  
Vol 146 (4) ◽  
pp. 1991-1998 ◽  
Author(s):  
Xin-Hua Liu ◽  
Alexander Kirschenbaum ◽  
Shen Yao ◽  
Alice C. Levine
Keyword(s):  
Cross Talk ◽  
Bone Cells ◽  
Osteoclast Differentiation ◽  
Nuclear Factor Κb ◽  
Receptor Activation ◽  
Nuclear Factor ◽  
Receptor Activator ◽  
Ep Receptor ◽  
Rank System ◽  
Cox 2

Abstract The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system is the dominant and final mediator of osteoclastogenesis. Abnormalities of this system have been implicated in the pathogenesis of many skeletal diseases. Cyclooxygenase (COX)-2 and prostaglandin (PG)E2, a major eicosanoid product of the COX-2-catalyzed pathway, play key roles in normal bone tissue remodeling. PGE2 exerts its actions by binding and activating the E series of prostaglandin (EP) receptor. Activation of EP2 and EP4 receptors is associated with PGE2-induced osteoclast differentiation. IL-6, a major proinflammatory cytokine, has also been reported to induce osteoclast differentiation. Although interactions between the COX-2/PGE2 and IL-6 systems have been described in bone cells, the mechanisms underlying these cooperative signaling pathways and the possible involvement of the OPG/RANKL/RANK system have not been fully elucidated. We demonstrate that COX-2, PGE2, and IL-6 stimulate osteoblast growth and osteoclast differentiation. Effects on osteoclast differentiation, particularly with IL-6, were most marked when osteoclast precursor cells were grown in coculture with osteoblasts, indicating a possible role of the RANK/RANKL/OPG system. COX-2 and PGE2 stimulated osteoclastogenesis through inhibition of OPG secretion, stimulation of RANKL production by osteoblasts, and up-regulation of RANK expression in osteoclasts. PGE2 stimulated IL-6 secretion by bone cells, whereas COX-2 inhibitors decreased this same parameter. IL-6, in turn, increased PGE2 secretion, COX-2, and EP receptor subtype expression in bone cells. Finally, IL-6 was the mediator of PGE2-induced suppression of OPG production by osteoblasts. These findings provide evidence for cross-talk between the PGE2 and IL-6 signaling enhance osteoclast differentiation via effects on the OPG/RANKL/RANK system in bone cells.

Determining and Overcoming Resistance to HIV Protease Inhibitors

2004 ◽  
Vol 4 (2) ◽  
pp. 137-152 ◽  
Author(s):  
Jana Prejdova ◽  
Milan Soucek ◽  
Jan Konvalinka
Keyword(s):  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors

A QSAR Study of HIV Protease Inhibitors Using Theoretical Descriptors

2010 ◽  
Vol 6 (4) ◽  
pp. 269-282 ◽  
Author(s):  
Subhash C. Basak ◽  
Denise Mills ◽  
Rajni Garg ◽  
Barun Bhhatarai
Keyword(s):  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors ◽  
Qsar Study

Aminodiol HIV protease inhibitors. 2. 1,1-Dimethyl-2-hydroxyethyl carbamate derivatives with enhanced potency

1995 ◽  
Vol 5 (5) ◽  
pp. 459-464 ◽  
Author(s):  
G.S. Bisacchi ◽  
S. Ahmad ◽  
M. Alam ◽  
A. Ashfaq ◽  
J. Barrish ◽  
...  
Keyword(s):  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors

Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors

1996 ◽  
Vol 6 (23) ◽  
pp. 2847-2852 ◽  
Author(s):  
Xiaoqi Chen ◽  
Lin Li ◽  
Dale J. Kempf ◽  
Hing Sham ◽  
Norman E. Wideburg ◽  
...  
Keyword(s):  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors

scholarly journals Additivity in the Analysis and Design of HIV Protease Inhibitors

2009 ◽  
Vol 52 (3) ◽  
pp. 737-754 ◽  
Author(s):  
Robert N. Jorissen ◽  
G. S. Kiran Kumar Reddy ◽  
Akbar Ali ◽  
Michael D. Altman ◽  
Sripriya Chellappan ◽  
...  
Keyword(s):  
Protease Inhibitors ◽  
Hiv Protease ◽  
Hiv Protease Inhibitors ◽  
Analysis And Design
Sign in / Sign up

Export Citation Format

Share Document